Get started
Author

Ana Callejo

Observed names: A. Callejo, Ana Callejo-Pérez, Ana Callejo‐Pérez, Á. Callejo
Observed institutions: Hospital de Sant Pau, Hospital Universitario de Burgos, Vall d'Hebron Hospital Universitari, Hospital Clínico Universitario Lozano Blesa, AstraZeneca (Spain), Hospital Universitario Río Hortega, Vall d'Hebron Institute of Oncology
ORCID: 0000-0003-2556-8412
Observed ORCID: 0000-0003-2556-8412
OpenAlex ID: A5000400774
Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
2022 · Patricia Iranzo, Ana Callejo, et al. · Frontiers in Medicine · 105
PDF
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
2023 · J. Remon, B. Besse, et al. · Annals of Oncology · 88
PDF
Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study
2022 · Mar Riveiro-Barciela, Ana Barreira-Díaz, et al. · Clinical Gastroenterology and Hepatology · 54
Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer
2020 · Joan Frigola, Alejandro Navarro, et al. · Molecular Oncology · 47
PDF
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
2024 · Jordi Remon, Benjamin Besse, et al. · Journal of Clinical Oncology · 36
Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).
2018 · Mariona Riudavets, Andrés Barba, et al. · Journal of Clinical Oncology · 32
An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury
2024 · Mar Riveiro‐Barciela, Ana Barreira‐Díaz, et al. · Alimentary Pharmacology & Therapeutics · 26
PDF
Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
2021 · Susana Cedres, Juan-David Assaf, et al. · Scientific Reports · 26
PDF
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer
2022 · Benjamin Solomon, Ana Callejo, et al. · Cancer Medicine · 24
PDF
Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence
2022 · Paula Jiménez-Fonseca, Enrique Gallardo, et al. · European Journal of Internal Medicine · 20
PDF
Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients
2020 · S. Cedrés, S. Ponce-Aix, et al. · Clinical & Translational Oncology · 17
Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients
2021 · Ana Callejo, Joan Frigola, et al. · Cancers · 14
PDF
Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy
2023 · Susana Cedres, Augusto Valdivia, et al. · Cancers · 12
PDF
The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate
2022 · Laia Aceituno, Juan Bañares, et al. · Frontiers in Medicine · 12
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial
2025 · Matthias Guckenberger, Isabelle Opitz, et al. · Lung Cancer · 11
Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer
2021 · Alex Martinez-Marti, Enriqueta Felip, et al. · British Journal of Cancer · 10
Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC
2023 · Caterina Carbonell, Joan Frigola, et al. · Molecular Oncology · 9
PDF
High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
2022 · Joan Frigola, Caterina Carbonell, et al. · Journal for ImmunoTherapy of Cancer · 9
PDF
Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient
2019 · I. Domingues, S. Cedres, et al. · Pulmonology · 9
PDF
First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study
2024 · Aida Piedra, Sergio Martínez-Recio, et al. · Frontiers in Oncology · 7
PDF
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial
2025 · R.A. Soo, K. Vervita, et al. · Lung Cancer · 6
Herpes simplex encephalitis in the context of immune checkpoint inhibitors: a complex interplay
2022 · Sofía Lallana, Daniel Sánchez-Tejerina, et al. · Acta Neurologica Belgica · 6
Risk factors for cancer-related cognitive impairment in breast and colorectal cancer patients who undergo chemotherapy
2023 · Patricia Iranzo, Ana Callejo, et al. · Anales del Sistema Sanitario de Navarra · 5
PDF
Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates
2019 · B. Solomon, A. Callejo, et al. · Annals of Oncology · 5
WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients
2019 · F.J. Ros Montana, P. Iranzo, et al. · Annals of Oncology · 5
Works count: 74
Citation count: 620
H-index: 12
I10-index: 16
Year
Topic
Type